Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:IMMP NASDAQ:NGNE NYSE:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$9.88+2.2%$8.72$3.96▼$9.89$275.76M0.6485,874 shs109,893 shsIMMPPrima BioMed$1.86-1.1%$1.71$1.32▼$2.71$273.02M1.8796,859 shs117,184 shsNGNENeurogene$22.34+6.5%$19.56$6.88▼$74.49$318.84M1.58188,580 shs466,560 shsOSTXOS Therapies$2.02+1.5%$2.08$1.12▼$7.00$63.92M-4.09697,063 shs226,305 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies0.00%+9.29%+7.63%+13.76%+113.85%IMMPPrima BioMed0.00%+8.14%+14.81%+8.77%-12.26%NGNENeurogene0.00%+25.36%+13.92%+11.45%-46.49%OSTXOS Therapies0.00%-1.46%-3.35%+8.02%-30.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$9.88+2.2%$8.72$3.96▼$9.89$275.76M0.6485,874 shs109,893 shsIMMPPrima BioMed$1.86-1.1%$1.71$1.32▼$2.71$273.02M1.8796,859 shs117,184 shsNGNENeurogene$22.34+6.5%$19.56$6.88▼$74.49$318.84M1.58188,580 shs466,560 shsOSTXOS Therapies$2.02+1.5%$2.08$1.12▼$7.00$63.92M-4.09697,063 shs226,305 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies0.00%+9.29%+7.63%+13.76%+113.85%IMMPPrima BioMed0.00%+8.14%+14.81%+8.77%-12.26%NGNENeurogene0.00%+25.36%+13.92%+11.45%-46.49%OSTXOS Therapies0.00%-1.46%-3.35%+8.02%-30.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 2.67Moderate Buy$13.3334.95% UpsideIMMPPrima BioMed 2.00Hold$7.00276.34% UpsideNGNENeurogene 2.56Moderate Buy$46.17106.65% UpsideOSTXOS Therapies 3.00Buy$18.00791.09% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, NGNE, IMMP, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/2/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$45.009/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/27/2025FENCAdherex TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMMPPrima BioMedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/12/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/2/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/27/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/21/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.008/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025FENCAdherex TechnologiesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$47.54M5.80$0.03 per share305.92($0.21) per share-47.05IMMPPrima BioMed$6.69M40.81N/AN/A$0.63 per share2.95NGNENeurogene$930K342.79N/AN/A$20.89 per share1.07OSTXOS TherapiesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$440K-$0.42N/AN/AN/A-35.05%N/A-23.92%11/6/2025 (Estimated)IMMPPrima BioMed-$39.78MN/A0.00N/AN/AN/AN/AN/AN/ANGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)OSTXOS Therapies-$7.79M-$0.79N/AN/AN/AN/AN/A-569.57%N/ALatest OSTX, NGNE, IMMP, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FENCAdherex Technologies-$0.06-$0.11-$0.05-$0.11$9.52 million$9.76 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A4.854.59IMMPPrima BioMedN/A11.69N/ANGNENeurogeneN/A18.0718.07OSTXOS TherapiesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%IMMPPrima BioMed2.32%NGNENeurogene52.37%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipFENCAdherex Technologies11.76%IMMPPrima BioMed3.07%NGNENeurogene11.64%OSTXOS Therapies10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1027.91 million24.63 millionOptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionableNGNENeurogene9014.27 million12.61 millionOptionableOSTXOS TherapiesN/A31.65 millionN/AN/AOSTX, NGNE, IMMP, and FENC HeadlinesRecent News About These CompaniesD. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSE:OSTX)October 2 at 2:32 AM | americanbankingnews.comD. Boral Capital Maintains OS Therapies (OSTX) Buy RecommendationOctober 1, 2025 | msn.comStrategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS TherapiesOctober 1, 2025 | tipranks.comOS Therapies Files Prospectus for Stock ResaleSeptember 30, 2025 | tipranks.comOS Therapies' (OSTX) Buy Rating Reiterated at D. Boral CapitalSeptember 30, 2025 | marketbeat.comOS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory UpdateSeptember 30, 2025 | newsfilecorp.comNOS Therapies (NYSE:OSTX) Shares Down 2.8% - Time to Sell?September 27, 2025 | marketbeat.comOS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDTSeptember 19, 2025 | newsfilecorp.comNOptimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical AdvancementsSeptember 16, 2025 | tipranks.comOS Therapies (NYSE:OSTX) Receives "Buy" Rating from D. Boral CapitalSeptember 14, 2025 | marketbeat.comOS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last VisitSeptember 12, 2025 | newsfilecorp.comNStonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)September 8, 2025 | newsfilecorp.comNOS Therapies to Participate in Upcoming Investor Conferences in September 2025September 3, 2025 | newsfilecorp.comNOS Therapies Raises $3.7M for OST-HER2 LaunchSeptember 2, 2025 | tipranks.comOS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 MeetingSeptember 2, 2025 | newsfilecorp.comNOS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 FinancingSeptember 2, 2025 | newsfilecorp.comNOS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025August 27, 2025 | newsfilecorp.comNOS Therapies Ends Equity Agreement with Square GateAugust 26, 2025 | tipranks.comOS Therapies Reports Progress in Osteosarcoma TreatmentAugust 25, 2025 | tipranks.comOS Therapies Terminates Equity Line of CreditAugust 25, 2025 | newsfilecorp.comNOS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details UnavailableAugust 19, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSTX, NGNE, IMMP, and FENC Company DescriptionsAdherex Technologies NASDAQ:FENC$9.88 +0.21 (+2.17%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$9.88 -0.01 (-0.05%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Prima BioMed NASDAQ:IMMP$1.86 -0.02 (-1.06%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.88 +0.02 (+1.34%) As of 10/3/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Neurogene NASDAQ:NGNE$22.34 +1.36 (+6.48%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$21.50 -0.84 (-3.76%) As of 10/3/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.OS Therapies NYSE:OSTX$2.02 +0.03 (+1.51%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.06 +0.04 (+2.23%) As of 10/3/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
